SELLAS Life Sciences Group, Inc. (SLS)
Stock Price:
$2.71 USD
0.04 (1.50%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed
After-hours: $2.87 +0.16 (5.90%) Oct 23, 5:55 PM
Key Info
| Market Cap |
25.64M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-20.19M |
| Shares Out |
9.46M |
| EPS (ttm) |
-4.95 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 23, 2020 |
| Last Price |
$2.71 |
| Previous Close |
$2.67 |
| Change ($) |
0.04 |
| Change (%) |
1.50% |
| Day's Open |
2.74 |
| Day's Range |
2.68 - 2.83 |
| Day's Volume |
66,617 |
| 52-Week Range |
1.46 - 10.89 |
More Stats
| Market Cap |
25.64M |
| Enterprise Value |
23.21M |
| Earnings Date (est) |
Nov 12, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
9.46M |
| Float |
8.96M |
| EPS (basic) |
-3.55 |
| EPS (diluted) |
-4.95 |
| FCF / Share |
-2.71 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
419,268 |
| Short Ratio |
2.00 |
| Short % of Float |
4.68% |
| Beta |
1.32 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
6.68 |
| Revenue |
n/a |
| Operating Income |
-19.99M |
| Net Income |
-20.19M |
| Free Cash Flow |
-18.21M |
| Net Cash |
2.43M |
| Net Cash / Share |
0.26 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-54.24% |
| ROE |
-222.82% |
| ROIC |
-455.20% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (2)
| Buy |
2 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$8.00*
(195.20% upside)
Low
8.00
Current: $2.71
High
8.00
Target: 8.00
*Average 12-month price target from 2 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -20.04 | -31.09 | -23.04 | -16.51 | -34.22 | -43.90 | -28.49 | -21.20 | -12.49 | -16.63 |
| Net Income | -19.29 | -27.67 | -23.75 | -17.68 | -63.90 | -36.61 | -76.68 | -34.97 | -11.49 | -11.99 |
| Shares Outstanding | 2.56 | 0.26 | 0.05 | 0.02 | 0.01 | - | - | - | - | - |
| Earnings Per Share | -10.92 | -157.72 | -522.00 | -933.00 | -12,346.24 | -9,195.92 | -25,502.55 | -16,801.68 | -9,600.96 | -20,102.01 |
| Operating Cash Flow | -17.64 | -30.42 | -10.99 | -11.85 | -48.16 | -42.87 | -28.93 | -20.97 | -14.67 | -10.26 |
| Capital Expenditures | - | - | - | - | -0.15 | -0.06 | -0.32 | - | -0.05 | -0.11 |
| Free Cash Flow | -17.64 | -30.42 | -10.99 | -11.85 | -48.31 | -42.93 | -29.25 | -20.97 | -14.72 | -10.36 |
| Cash & Equivalents | 7.38 | 5.45 | 12.75 | 6.05 | 30.13 | 23.85 | 47.99 | 35.59 | 11.54 | 6.91 |
| Total Debt | 0.22 | - | 10.99 | 7.37 | 4.74 | 8.40 | 9.89 | 0.06 | 0.57 | 0.07 |
| Net Cash / Debt | 7.16 | 5.45 | 1.76 | -1.32 | 25.39 | 15.45 | 38.10 | 35.53 | 10.97 | 6.84 |
| Assets | 16.61 | 16.92 | 33.53 | 6.42 | 82.14 | 80.49 | 87.98 | 54.99 | 30.97 | 7.48 |
| Liabilities | 10.52 | 11.67 | 31.46 | 11.42 | 68.63 | 43.43 | 82.09 | 27.23 | 20.86 | 5.05 |
| Book Value | 6.09 | 5.25 | 2.07 | -5.00 | 13.51 | 37.06 | 5.89 | 27.76 | 10.11 | 2.43 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
SELLAS Life Sciences Group, Inc. |
| Country |
United States |
| Employees |
5 |
| CEO |
Angelos M. Stergiou |
Stock Information
| Ticker Symbol |
SLS |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: SLS |
Description
SELLAS Life Sciences Group, a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a wilms tumor 1 targeting peptide-based cancer immunotherapeutic agent, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and is in various development phases as a potential treatment for ovarian cancer. It also develops nelipepimut-S that is in Phase 2b clinical trials for the treatment of breast cancer. The company has strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. SELLAS Life Sciences Group, Inc. was founded in 2012 and is headquartered in New York, New York.